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Lung cancer is the second most common cancer 
related death in America. Non-small cell lung cancer 
(NSCLC) is the more common variant of lung cancer, 
and represents roughly 85-90% of diagnosed lung 
cancers.  
 
Several mutations have been studied in NSCLC, 
including EML4-ALK fusion protein abnormalities, 
EGFR, K-Ras, and BRAF mutations.  
 
ALK abnormalities, which are the target of several new 
therapies, are found in approximately 5% of NSCLC 
patients.  
 
Unlike the typical population at risk for developing lung 
cancer, ALK positive NSCLC is seen more frequently in 
young adults and those who have smoked fewer than 
100 cigarettes or who have smoked less than 10 to 15 
pack-years.  
 
 Crizotinib was the first drug available for NSCLC that 
was positive for ALK mutations.  Accelerated approval 
for crizotinib was granted by the FDA in August 2011, 
with regular approval being granted in November 2013, 
for locally advanced or metastatic NSCLC that is ALK 
positive.  
 
Ceritinib is a second generation targeted therapy for 
ALK positive NSCLC. In April 2014, the FDA granted 
accelerated approval for ceritinib in the treatment of 
ALK positive NSCLC in patients who experience 
progression while being treated with crizotinib, or those 
who were intolerant to crizotinib. 
 
 
  
The purpose of this poster is to provide a summary of 
data on ceritinib, that shows exceptional potency 
against ALK mutations, and it’s promising ability to 
overcome resistance developed during crizotinib 
therapy. 
  
PubMed searches and information from package inserts for 
Xalkori ® (crizotinib) and Zykadia ® (ceritinib) were used to find 
major clinical trials. These trials studied the use of crizotinib as a 
treatment option for ALK-Rearranged (ALK Positive) Non-Small 
Cell Lung Cancer (NSCLC) and the use of ceritinib in crizotinib-
resistant NSCLC. Results from the studies were used to 
determine the potency of ceritinib over that of crizotinib. 
  
A conclusion can be drawn from a review of 
the Phase I studies; which earned ceritinib its FDA 
indication for use in ALK positive NSCLC patients, 
who experienced progression while being treated 
with crizotinib, or were intolerant to crizotinib that, 
ceritinib is 20 times more potent than crizotinib. 
 
Further clinical trials are currently being conducted 
to evaluate the efficacy of ceritinib as compared to 
standard chemotherapy regimens in both treated 
and untreated NSCLC.9, 10 Also, a new phase I trial 
is testing the combination of ceritinib and an 
experimental Hsp90 inhibitor. 
 
The future of targeted therapy for NSCLC looks 
promising. 
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Ceritinib (LDK378) binds to ALK a transmembrane  receptor tyrosine 
kinase and neutralizes it to prevent it from transmitting extracellular 
growth factor signaling to intracellular signaling cascades. The lack 
of binding of DTN/MK ligand to ALK prevents its activation thereby 
leading to loss of signaling through RAS, RAF, MEK, ERK, PI3K, 
AKT, mTOR, STAT3/5 pathways. The resulting effect of Ceritinib is 
increased apoptosis and decreased proliferation of lung cells 
expressing the ALK mutations. 
Results of Four Major Trials for bevacizumab use in GBM 
Study  Study Design (# of 
patients) 
Methods Endpoint(s) Resutls 
Crizotinib 
Studies 
Phase I       trial Crizotinib was 
evaluated in 82 
patients with ALK 
positive NSCLC 
 
 
Crizotinib 
 vs  
 IV pemetrexed or 
docetaxel in adults who 
had progressed on a 
prior platinum-based 
therapy  
Overall Response  
Rate       (ORR) 
 
 
 
 
progression free 
survival 
(PFS)  
Response  
Rate 
(RR) 
ORR of Crizotinib was 
57% 
 
 
 
 
PFS for crizotinib was              
7.7 months 
PFS for chemotherapy 
was  
3 months 
RR for Crizotinib was 
60% 
RR for chemotherapy 
was 20% 
Ceritinib 
Studies 
 
Phase I 
trial 
Ceritinib was evaluated 
in patients with 
advanced NSCLC who 
were either crizotinib 
naïve or had failed 
crizotinib therapy  
 
 
 
 
 
 
 
 
 
Crizotinib  
Vs 
 ceritinib in animal 
models bearing an ALK 
rearranged NSCLC cell 
line.  
 
 
Progression free 
survival (PFS) 
 
 
 
 
 
 
Overall response rate 
(ORR) 
 
 
 
 
 
Tumor regression 
(TR)  
PFS in patients 
previously treated with 
crizotinib was 6.9 
months. PFS in 
crizotinib naïve 
patients was 10.4 
months  
 
 
ORR among all 
participants 58% which 
is comparable to that of 
crizotinib 57%  
 
 
 
Tumors recurred in 
mice after 11 days in 
the crizotinib arm 
 Tumors recurred in 
mice after at least 4 
months in the ceritinib 
arm 
Molecular analysis was done on crizotinib resistant ALK rearranged 
NSCLC, which yielded seven different mutations that lead to acquired 
resistance. It is suggested that this acquired resistance emerges as 
mutations in secondary sites that ultimately affect the binding of crizotinib, 
and may arise through various mechanisms including chronic crizotinib 
exposure. In many of the crizotinib-resistant cell lines studied, ceritinib 
was able to overcome these resistances and showed efficacy in the cell 
lines; however, ceritinib was unable to overcome all resistances. 
